TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05498493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education Program
Description: The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
Study: NCT04445792

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study: NCT06329791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001
Description: AZR-MD-001 sterile ophthalmic ointment 0.5%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: AZR-MD-001 Vehicle
Study: NCT06654726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldafermin
Description: aldafermin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05619159

Intervention type: DEVICE
Intervention: microscopic pathological evaluation
Description: description of moesin expression between endometrial hyperplasia and endometrial carcinoma

Intervention type: DEVICE
Intervention: microscopic pathological evaluation
Description: description of moesin expression between endometrial hyperplasia and endometrial carcinoma
Study: NCT06556992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT Teens
Description: This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
Study: NCT05546502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Protein Subunit Recombinant Vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Covovax
Study: NCT05053061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application program for pulmonary rehabilitation
Description: Exercise videos for pulmonary rehabilitation
Study: NCT04856527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapist support
Description: Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
Study: NCT05196035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Finerenone in different doses, treatment duration will be 180±7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to finerenone, treatment duration will be 180±7 days
Study: NCT06173869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Description: FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GONAL-F
Description: GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed.
Study: NCT05428046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MHL intervention
Description: The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
Study: NCT04345393

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Transformation Network (DTN) Program
Description: Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Transformation Network (DTN) Program
Description: Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
Study: NCT05574946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
Study: NCT06607939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORB-021
Description: ORB-021 is dosed via IV infusion
Study: NCT06609161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate Oral Formulation 1 (Reference)
Description: Formulation 1 (FM1) powder for oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate Oral Formulation 2 (Test)
Description: Formulation 2 (FM2) powder for oral suspension.
Study: NCT06612229

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue
Description: In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
Study: NCT04895709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986340
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986340
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986340
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986340
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986340
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558-01
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558-01
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days
Study: NCT06615856

Intervention type: OTHER
Intervention: Questionnaire
Description: Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire
Study: NCT06676579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacopan
Description: Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (drug)
Description: Methylprednisolone 1g intravenous on day +1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (drug)
Description: Methylprednisolone 1g intravenous on day +1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
Study: NCT06615869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral Administration.
Study: NCT05911750

Intervention type: DIAGNOSTIC_TEST
Intervention: Anal pap smear and oral swab for cytology and HPV testing
Description: Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
Study: NCT05211063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron extract (Crocus sativus)
Description: Daily intake of one tablet for 42 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of one tablet for 42 days.
Study: NCT06678646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow ultrasound-guided surgery
Description: Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
Study: NCT06336148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTM-838
Description: Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
Study: NCT06683573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D Kidney model
Description: Brief provider led counseling and education on Chronic Kidney Disease (CKD) and hypertension guided by use of 3D kidney model visual aid

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard provider led counseling and education on CKD and hypertension
Study: NCT05328908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab-relatlimab FDC
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: Specified dose on specified days
Study: NCT05073250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI376
Description: IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
Study: NCT05418634

Intervention type: OTHER
Intervention: point of care EEG
Description: For pocEEG, scalp electrodes are applied in five locations.

Intervention type: OTHER
Intervention: point of care EEG
Description: For pocEEG, scalp electrodes are applied in five locations.
Study: NCT05037773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention targeting parental reminiscing style
Description: 8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention targeting parental reminiscing style
Description: 8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
Study: NCT03557697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Intervention
Description: Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
Study: NCT06193954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasoStar guidewire system
Description: The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a wire with an electromagnetic source.
Study: NCT05878704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Oral
Study: NCT06085339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media
Description: The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
Study: NCT04847596

Intervention type: OTHER
Intervention: Ofatumumab
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: Covid-19 vaccine
Description: Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
Study: NCT06698250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanzalintinib
Description: Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanzalintinib
Description: Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
Study: NCT06467643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite
Description: Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite
Description: Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
Study: NCT05329987

Intervention type: OTHER
Intervention: Rehabilitation
Description: Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
Study: NCT05764356

Intervention type: GENETIC
Intervention: Detection of genotype and RNA profile in platelet and white blood cell
Description: Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing

Intervention type: GENETIC
Intervention: Detection of genotype and RNA profile in platelet and white blood cell
Description: Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing

Intervention type: OTHER
Intervention: Indicators test related to coagulation function
Description: Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.

Intervention type: OTHER
Intervention: Indicators test related to platelet function
Description: Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
Study: NCT06382974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyst enucleation and bone grafting
Description: cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
Study: NCT01603810

Intervention type: OTHER
Intervention: OCT
Description: Optical coherence tomography of periocular basal cell carcinoma
Study: NCT05428046

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Description: Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
Study: NCT06547099

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tau PET
Description: Tau PET (flortaucipir)
Study: NCT06534008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise intervention
Description: All participants will be given the same 12-week distance-based exercise intervention.
Study: NCT06508619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring
Description: Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication